BIO Priorities Include Appropriate Pricing, Chair Mullen Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Biotechnology Industry Organization will also work to strengthen the intellectual property system, the exec tells BIO’s annual meeting.
You may also be interested in...
Amgen To Issue Biotech Cost-Effectiveness Study For Key Therapeutic Areas
The “Value of Biotechnology” study will examine the impact of biotech products on the social and economic burden of diseases such as asthma, stroke and diabetes.
Amgen To Issue Biotech Cost-Effectiveness Study For Key Therapeutic Areas
The “Value of Biotechnology” study will examine the impact of biotech products on the social and economic burden of diseases such as asthma, stroke and diabetes.
Genentech Pricing Strategy Is “Good For Society,” CEO Says
Levinson defends the high cost of targeted cancer treatments while suggesting the price of Avastin will increase.